All Q2 FY26 results →

RP

Royalty Pharma plc

Q2 FY26Pharmaceuticals

Royalty Pharma plc Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹54

Market cap₹31.4K Cr

P/E28.3

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueModerate growth

MarginMargins steady

CapexCapex planned

Order bookOrder book rising

The short version

- Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven by diversified and expanding biopharma royalty market. - Royalty Pharma raised its full-year 2026 financial guidance, expecting portfolio receipts between $3.325 billion and $3.45 billion, reflecting 4% to 8% growth in royalty receipts.

From Royalty Pharma plc's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth

Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven by diversified and expanding biopharma royalty market.
Full-year 2026 portfolio receipts guidance was raised to $3.325 billion - $3.45 billion, reflecting 4%-8% growth in royalty receipts despite headwinds from loss of exclusivity and biosimilar launches.
Growth fueled by strong product momentum (e.g., Tremfya, Voranigo, Evrysdi) and pipeline developments with multiple pivotal readouts anticipated in 2026-2027.
Expansion into R&D co-funding with global biopharma and in China is expected to accelerate capital deployment and future revenue streams.
Pipeline includes promising therapies with blockbuster potential, e.g., cardiovascular and multiple sclerosis drugs, expected to unlock substantial value.

2 more points from Royalty Pharma plc's call on revenue

Create a free account to keep reading this call

Profitability & Margins

Royalty Pharma raised its full-year 2026 financial guidance, expecting portfolio receipts between $3.325 billion and $3.45 billion, reflecting 4% to 8% growth in royalty receipts.
The company anticipates strong low-volatility top and bottom line growth through 2030 and beyond.
Return on invested capital stood at 14.1%, and return on invested equity at 19.7% (last 12 months ending Q1 2026), indicating attractive returns.
Continued deployment of capital into attractive royalty deals ($528 million in Q1 2026) supports growth.
Growth is fueled by multiple upcoming pivotal readouts and product launches in 2026-2027.
Increasing emphasis on R&D co-funding with global biopharma and expansion into China represent significant growth opportunities.

2 more points from Royalty Pharma plc's call on margins

Create a free account to keep reading this call

See what Royalty Pharma plc said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Royalty Pharma has significant capital flexibility, with the capability to invest around $30 billion.
Annual guided investment is ~$2 billion to $2.5 billion.
An additional $10 billion capacity exists to increase investments if attractive opportunities arise.
Potential to deploy up to $20 billion over the next 5 years in royalty acquisitions.
New strategic focuses include expansion into China, viewed as a key driver of capital deployment and growth.
Increasing activity in co-funding R&D with large global biopharma companies, which was previously underrepresented in capital deployment guidance.
Recent deals with J&J and Teva highlight $1 billion of announced value in R&D co-funding.

2 more points from Royalty Pharma plc's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

Royalty Pharma currently has $9.2 billion of investment-grade debt with a weighted average duration of around 12 years.
They have a $1.8 billion revolver facility, which is currently undrawn.
Total financial flexibility is approximately $4 billion, combining cash on hand, cash generated by the business, and access to debt markets.
The leverage ratio stands at 2.9x total debt to adjusted EBITDA, indicating low leverage and significant financial capacity.

2 more points from Royalty Pharma plc's call on fundraising

Create a free account to keep reading this call

See what Royalty Pharma plc said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising

Royalty Pharma has significant capital deployment capacity, with the ability to invest around $30 billion overall.
Of this, approximately $12 billion is guided at $2 billion to $2.5 billion per year.
Additional $10 billion capacity exists for increasing investments if opportunities arise, potentially deploying $20 billion over the next five years in royalty acquisitions.
Recent deals with big pharma (e.g., J&J, Teva) totaling $1 billion announced in Q1 indicate growing co-funding opportunities.
The China market is emerging as a new driver for capital deployment, with management actively building a platform and expecting significant deal flow.

2 more points from Royalty Pharma plc's call on order book

Create a free account to keep reading this call

Others in Pharmaceuticals this season

Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

Compare:vs AstraZeneca PLC vs Johnson & Johnson vs Novartis AG

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Royalty Pharma plc and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Royalty Pharma plc Q2 FY26 results?

- Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven by diversified and expanding biopharma royalty market. - Royalty Pharma raised its full-year 2026 financial guidance, expecting portfolio receipts between $3.325 billion and $3.45 billion, reflecting 4% to 8% growth in royalty receipts.

What is Royalty Pharma plc share price analysis?

Royalty Pharma plc currently shows a below-average growth signal. The stock trades at a P/E of 28.3 with a market cap of $31,371. Investors should review the full earnings analysis for detailed insights.

Is Royalty Pharma plc planning capital expenditure?

- Royalty Pharma has significant capital flexibility, with the capability to invest around $30 billion.

Keep Royalty Pharma plc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.